Transfusion Medicine Reviews
Volume 17, Issue 1 , Pages 57-68 , January 2003

The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility

  • Miguel Lozano

      Affiliations

    • Department of Hemotherapy and Hemostasis, Biomedical Diagnostic Center, Agustí Pi i Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clínico of Barcelona, University of Barcelona, Barcelona, Spain
    • Blood Transfusion Center and Tissue Bank, Tarragona, Spain
    • Corresponding Author InformationAddress reprint requests to Miguel Lozano, MD,Hospital Clínico Barcelona, Department Hemotherapy and Hemostasis, Villarroel 170, 08036 Barcelona, Spain.
    • ,
  • Joan Cid

      Affiliations

    • Department of Hemotherapy and Hemostasis, Biomedical Diagnostic Center, Agustí Pi i Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clínico of Barcelona, University of Barcelona, Barcelona, Spain
    • Blood Transfusion Center and Tissue Bank, Tarragona, Spain

References 

  1. (abstr 957) Klein E, Djerassi I, Farber S. Maintenance of normal platelet levels in recipients of multiple transfusions of platelets from incompatible blood. In: Proceedings of the VIIth Congress of the International Society of Hematology. Rome, Italy,. September 7–13, 1958;
  2. Djerassi I, Farber S, Evans AE. Transfusion of fresh platelet concentrates to patients with secondary thrombocytopenia. N Engl J Med. 1963;268:221–226
  3. (letter) Gurevitch J, Nelken D. ABO groups in blood platelets. Nature. 1954;173:356
  4. Dunstan RA, Simpson MB, Knowles RW, et al. The origin of ABH antigens on human platelets. Blood. 1985;65:615–619
  5. Santoso S, Kiefel V, Mueller-Eckhardt C. Blood group A and B determinants are expressed on platelet glycoproteins IIa, IIIa, and Ib. Thromb Haemost. 1991;65:196–201
  6. Skogen B, Rossebo HB, Husebekk A, et al. Minimal expression of blood group A antigen on thrombocytes from A2 individuals. Transfusion. 1988;28:456–459
  7. Ogasawara K, Ueki J, Takenaka M, et al. Study on the expression of ABH antigens on platelets. Blood. 1993;82:993–999
  8. Dunstan RA, Mansbach CM. Biochemical characterisation of A blood group activity on human platelets. Vox Sang. 1985;49:149–153
  9. Duquesnoy RJ, Filip DJ, Aster RH. Influence of HLA-A2 on the effectiveness of platelet transfusions in alloimmunized thrombocytopenic patients. Blood. 1977;50:407–412
  10. Dunstan RA, Simpson MB. Heterogeneous distribution of antigens on human platelets demonstrated by fluorescence flow cytometry. Br J Haematol. 1985;61:603–609
  11. Aster RH. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood. 1965;26:732–743
  12. Pfisterer H, Thierfelder S, Stich W. ABO Rh blood groups and platelet transfusion. Blut. 1968;17:1–5
  13. Kelton JG, Hamid C, Aker S, et al. The amount of blood group A substance on platelets is proportional to the amount in the plasma. Blood. 1982;59:980–985
  14. Duquesnoy RJ, Anderson AJ, Tomasulo PA, et al. ABO compatibility and platelet transfusions of alloimmunized thrombocytopenic patients. Blood. 1979;54:595–599
  15. Lee EJ, Schiffer CA. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion. 1989;29:384–389
  16. Heal JM, Blumberg N, Masel D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood. 1987;70:23–30
  17. Heal JM, Rowe JM, Blumberg N. ABO and platelet transfusion revisited. Ann Hematol. 1993;66:309–314
  18. Klumpp TR, Herman JH, Innis S, et al. Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation. Bone Marrow Transplant. 1996;17:1035–1041
  19. Lin Y, Callum JL, Coovadia AS, et al. Transfusion of ABO-nonidentical platelets is not associated with adverse clinical outcomes in cardiovascular surgery patients. Transfusion. 2002;42:166–172
  20. Heal JM, Masel D, Rowe JM, et al. Circulating immune complexes involving the ABO system after platelet transfusion. Br J Haematol. 1993;85:566–572
  21. In: Gorlin JB editors. Standards for Blood Banks and Transfusion Services. 20th Edition. Bethesda, MD: American Association of Blood Banks; 2000;
  22. Simon TL, Sierra ER. Concentration of platelet units into small volumes. Transfusion. 1984;24:173–175
  23. Moroff G, Friedman A, Robkin-Kline L, et al. Reduction of the volume of stored platelet concentrates for use in neonatal patients. Transfusion. 1984;24:144–146
  24. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1519–1538
  25. Zoes C, Dube VE, Miller HJ, et al. Anti-Al in the plasma of platelet concentrates causing a hemolytic reaction. Transfusion. 1977;17:29–32
  26. McLeod BC, Sassetti RJ, Weens JH, et al. Haemolytic transfusion reaction due to ABO incompatible plasma in a platelet concentrate. Scand J Haematol. 1982;28:193–196
  27. Conway LT, Scott EP. Acute hemolytic transfusion reaction due to ABO incompatible plasma in a plateletapheresis concentrate. Transfusion. 1984;24:413–414
  28. Pierce RN, Reich LM, Mayer K. Hemolysis following platelet transfusions from ABO-incompatible donors. Transfusion. 1985;25:60–62
  29. Ferguson DJ. Acute intravascular hemolysis after a platelet transfusion. Can Med Assoc J. 1988;138:523–524
  30. Reis MD, Coovadia AS. Transfusion of ABO-incompatible platelets causing severe haemolytic reaction. Clin Lab Haematol. 1989;11:237–240
  31. Murphy MF, Hook S, Waters AH, et al. Acute haemolysis after ABO-incompatible platelet transfusions. Lancet. 1990;335:974–975
  32. Mair B, Benson K. Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets. Transfusion. 1998;38:51–55
  33. McManigal S, Sims KL. Intravascular hemolysis secondary to ABO incompatible platelet products. An underrecognized transfusion reaction. Am J Clin Pathol. 1999;111:202–206
  34. Larsson LG, Welsh VJ, Ladd DJ. Acute intravascular hemolysis secondary to out-of-group platelet transfusion. Transfusion. 2000;40:902–906
  35. Valbonesi M, De Luigi MC, Lercari G, et al. Acute intravascular hemolysis in two patients transfused with dryplatelet units obtained from the same ABO incompatible donor. Int J Artif Organs. 2000;23:642–646
  36. CBBS, e-Network forum. Available at Reducing supernatant plasma of pooled platelets before administration to ABO-incompatible adult recipients. Accessed May 12, 2002 PltpoolPlasma.html">
  37. Wallace EL, Churchill WH, Surgenor DM, et al. Collection and transfusion of blood and blood components in the United States, 1994. Transfusion. 1998;38:625–636
  38. Ervin DM, Young LE. Dangerous universal donors. I. Observation on destruction of recipient's A cells after transfusion of group O blood containing high titer of A antibodies of immune type no easily neutralizable by soluble A substance. Blood. 1950;5:61–73
  39. Benjamin RJ, Mcgurk S, Ralston MS, et al. ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion. 1999;39:179–187
  40. Benjamin RJ, Antin JH. ABO-incompatible bone marrow transplantation: The Transfusion of incompatible plasma may exacerbate regimen-related toxicity. Transfusion. 1999;39:1273–1274
  41. Blumberg N, Heal JM, Hick GL, et al. Association of ABO-mismatched platelet transfusions with morbidity and mortality in cardiac surgery. Transfusion. 2001;41:790–793
  42. Marini AM, Matassi G, Raynal V, et al. The human Rhesus-associated RhAG protein and a kidney homologue promote ammonium transport in yeast. Nat Genet. 2000;26:341–344
  43. Dunstan RA, Simpson MB, rosse WF. Erythrocyte antigens on human platelets. Absence of Rh, Duffy, Kell, Kidd, and Lutheran antigens. Transfusion. 1984;24:243–246
  44. Fijnheer R, Pietersz RNI, de Korte D, et al. Platelet activation during preparation of platelet concentrates: A comparison of the platelet-rich plasma and the buffy coat methods. Transfusion. 1990;30:634–638
  45. Lozano M, Estebanell E, Cid J, et al. Platelet concentrates prepared and stored under currently optimal conditions: Minor impact on platelet adhesive and cohesive functions after storage. Transfusion. 1999;39:951–959
  46. Goldfinger D, McGinniss MH. Rh-incompatible platelet transfusions—Risks and consequences of sensitizing immunosuppressed patients. N Engl J Med. 1971;284:942–944
  47. Cid J, Ortin X, Elies E, et al. Absence of anti-D alloimmunization in hematologic patients after D-incompatible platelet transfusions. Transfusion. 2002;42:173–176
  48. Lichtiger B, Surgeon J, Rhorer S. Rh-incompatible platelet transfusion therapy in cancer patients. A study of 30 cases. Vox Sang. 1983;45:139–143
  49. Heim MU, Böck M, Kolb HJ, et al. Intravenous anti-D gammaglobulin for the prevention of Rhesus isoimmunization caused by platelet transfusion in patients with malignant diseases. Vox Sang. 1992;62:165–168
  50. Atoyebi W, Mundy N, Croxton T, et al. Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates?. Brit J Haematol. 2000;111:980–983
  51. Molnar R, Johnson R, Sweat LT, et al. Absence of D alloimmunization in D- pediatric oncology patients receiving D-incompatible single-donor platelets. Transfusion. 2002;42:177–182
  52. Pollack W, Ascari WQ, Crispen JF, et al. Studies on Rh prophylaxis. II. Rh immune prophylaxis after transfusion with Rh-positive blood. Transfusion. 1971;11:340–344
  53. Urbaniak SJ, Robertson AE. A successful program of immunizing Rh-negative male volunteers for anti-D production using frozen/thawed blood. Transfusion. 1981;21:64–69
  54. Bowman HS. Effectiveness of prophylactic Rh immunosuppression after transfusion with D-positive blood. Am J Obstet Gynecol. 1976;124:80–84
  55. Mollison PL, Hughes-Jones NC, Lindsay M, et al. Suppression of primary RH immunization by passively-administered antibody. Experiments in volunteers. Vox Sang. 1969;16:421–439
  56. Woodrow JC, Finn R, Krevans JR. Rapid clearance of Rh positive blood during experimental Rh immunisation. Vox Sang. 1969;17:349–361
  57. Samson D, Mollison PL. Effect on primary Rh immunization of delayed administration of anti-Rh. Immunology. 1975;28:349–357
  58. Contreras M, Mollison PL. Failure to augment primary Rh immunization using a small dose of “passive” IgG anti-Rh. Br J Haematol. 1981;49:371–381
  59. The Rh blood group system (and LW). In: Mollison PL, Englefriet CP, Contreras M editor. Blood Transfusion in Clinical Medicine. ed 10. London: Blackwell Science; 1997;p. 151–185
  60. Shirey RS, King KE: Alloimmunization to blood group antigens, in Anderson KC, Ness PM (eds): Scientific Basis of Transfusion Medicine. Implications for clinical practice. Philadelphia, PA, 2000, pp. 393–400
  61. Gunson HH, Stratton F, Cooper DG, et al. Primary immunization of Rh-negative volunteers. Br Med J. 1970;1:593–595
  62. Archer GT, Cooke BR, Mitchell K, et al. Hyper-immunisation des donneurs de sang pour la production des gammaglobulines anti-Rh(D). Rev Franç Transfus. 1969;12:341–350
  63. Gunson HH, Stratton F, Phillips PK. The use of modified cells to induce an anti-Rh response. Br J Haematol. 1971;21:683–694
  64. Baldwin ML, Ness PM, Scott D, et al. Alloimmunization to D antigen and HLA in D-negative immunosuppressed oncology patients. Transfusion. 1988;28:330–333
  65. McLeod BC, Piehl MR, Sassetti RJ. Alloimmunization to RhD by platelet transfusion in autologous bone marrow transplant recipients. Vox Sang. 1990;59:185–189
  66. Schonewille H, Haak HL, vanZijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion. 1999;39:763–771
  67. Stern HS, Goodman S, Berger M. Experimental isoimmunization to hemoantigens in man. J Immunol. 1961;87:189–198
  68. Stern K, Davidsohn I, Masaitis L. Experimental studies on Rh immunization. Am J Clin Pathol. 1956;26:833–943
  69. Menitove JE. Immunoprophylaxis for D-patients receiving platelet transfusions from D+ donors. Transfusion. 2002;42:136–138
  70. (letter) Zeiler T, Wittmann G, Zingsem J, et al. A dose of 100 IU intravenous anti-D gammaglobulin is effective for the prevention of Rh(D) immunisation after Rh(D)-incompatible single donor platelet transfusion. Vox Sang. 1994;66:243
  71. Ramsey G, Hahn LF, Cornell FW, et al. Low rate of Rhesus immunization from Rh-incompatible blood transfusions during liver and heart transplant surgery. Transplantation. 1989;47:993–995
  72. Cummins D, Contreras M, Amin S, et al. Red cell alloantibody development associated with heart and lung transplantation. Transplantation. 1995;59:1432–1435
  73. Casanueva M, Valdes MD, Ribera MC. Lack of alloimmunization to D antigen in D-negative immunosuppressed liver transplant recipients. Transfusion. 1994;34:570–572
  74. Pollack W, Gorman JG, Hager HJ, et al. Antibody-mediated immune suppression to the Rh factor: Animal models suggesting mechanism of action. Transfusion. 1968;8:134–145
  75. Anderson B, Shad AT, Gootenberg JE, et al. Successful prevention of post-transfusion Rh alloimmunization by intravenous Rho (D) immune globulin (WinRho SD). Amer J Hematol. 1999;60:245–247
  76. Sandler SG. Treating immune thrombocytopenic purpura and preventing Rh alloimmunization using intravenous rho (D) immune globulin. Transfus Med Rev. 2001;15:67–76
  77. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228–1233
  78. (letter) Lawlor E, Columb G. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med. 1999;341:762
  79. (letter) Bonis PA. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med. 1999;341:763
  80. Birch GA, Alving BM: Plasma derivatives and adverse reactions in, Popovsky MA (ed): Transfusion Reactions (ed 2). Bethesda, MD, AABB Press, pp 401–404
  81. Bowman JM. The advantages of intravenous Rh-immune globulin. Clin Obstet Gynecol. 1982;25:341–347
  82. Tarantino MD, Madden RM, Fennewald DL, et al. Treatment of childhood acute immune thrombocytopenic purpura with anti- D immune globulin or pooled immune globulin. J Pediatr. 1999;134:21–26
  83. Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh-o(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood. 2000;95:2523–2529
  84. Imbach P, Kuhne T. Sequelae of treatment of ITP with anti-D (Rho) immunoglobulin. Lancet. 2000;356:447–448
  85. Rushin J, rumsey DH, Ewing CA, et al. Detection of multiple passively acquired alloantibodies following infusions of IVRh immune globulin. Transfusion. 2000;40:551–554
  86. Wright J, Freedman J, Lim FC, et al. Crossmatch difficulties following the prophylactic use of Rh immune globulin. Can Med Assoc J. 1979;120:1235–1238
  87. Stroncek DF, Procter JL, Moses L, et al. Intravenous Rh immune globulin prevents alloimmunization in D-granulocyte recipients but obscures the detection of an alloanti-K. Immunohematology. 2001;17:37–41
  88. Rizk A, Gorson KC, Kenney L, et al. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion. 2001;41:264–268
  89. Rivat L, Rivat C, Parent M, et al. Accident survenu après injection de gamma-globulines anti-Rh dû à la présence d'anticorps anti-gamma A. Presse Med. 1970;78:2072
  90. Branch DW, Guyman G, Scott JR. Failure to prevent rhesus immunisation with rhesus immune globulin after incompatible blood transfusion. Lancet. 1985;1:393–394
  91. Bowman JM, Pollock JM. Failures of intravenous Rh immune globulin prophylaxis: An analysis of the reasons for such failures. Transfus Med Rev. 1987;1:101–112
  92. Guide to the preparation, use and quality assurance of blood components. Strasbourg, France: Council of Europe Publishing; 2001;

PII: S0887-7963(03)80005-6

doi: 10.1053/tmrv.2003.50003

Transfusion Medicine Reviews
Volume 17, Issue 1 , Pages 57-68 , January 2003

Article Tools